Novel, oral bone-protecting compounds for the treatment of rheumatoid arthritis

Modern Biosciences' novel bone-protecting agents programme aims to develop a new treatment for rheumatoid arthritis (RA) and other osteoimmune disorders. Rheumatoid arthritis affects 1% of the population worldwide and up to 40% of patients don’t respond to current treatments. Modern Biosciences' compounds represent a new approach to treating RA via the reduction of inflammation and the reversal of bone damage. MBS’ compounds are orally administered, which makes them more convenient to use than the most rapidly growing class of drugs for RA, the injectable biologics. They also show good activity in combination with existing treatments and may enhance the activity of existing agents and their duration of use. The aim of this project is to progress a candidate compound into clinical trials in patients with rheumatoid arthritis, demonstrating its safety and effectiveness.